Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.72 EPS, up 2.78% or $0.02 from last year’s $-0.74 per share.

At the moment 7 analysts are watching Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 3 rate it “Buy”, 2 “Outperform”, 1 “Underperform”, 1 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 7 analysts have a mean sales target of 0.05 million. For the quarter ending Sep-16, 7 analysts have a mean sales target of 0.05 million whilst for the year ending Dec-16, 7 analysts have a mean target of 0.17 million.

In terms of earnings per share, 7 analysts have a -0.76 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 7 analysts have a -0.77 EPS mean target and for the quarter ending Sep-16 there are 6 estimates of -3.14 EPS.

The biggest institutional shareholders in Karyopharm Therapeutics Inc. include Fidelity Management and Research Company which owns 5 million shares in the company valued at $71.02 million. Franklin Advisers, Inc. is the second biggest holder with 5 million shares currently valued at 68.49 million whilst Palo Alto Investors, LLC has 3 million shares valued at 41.24 million.

Total shares held by institutions as of the most recent company filings are 24,432,197 with a reported 2,849,648 bought and 13,621,080 sold. These holdings make up 68.09% of the company’s outstanding shares.

Currently insiders hold 1,403,407 shares in the business which makes up 3.91% of shares. The biggest holder currently is Dr. Sharon Shacham, M.B.A.,PhD who owns 763,963 shares (2.13% of those outstanding), whilst Dr. Michael G. Kauffman,M.D.,PhD holds 562,596 (1.57% of shares outstanding) and Paul Brannelly holds 66,136 (0.18% of shares outstanding).

The stock decreased 1.38% or $0.11 during the last trading session, hitting $9.56. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has fallen 64.23% over the past 6 months and is downtrending.